Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80

Burlando, Martina; Herzum, Astrid; Cozzani, Emanuele; Parodi, Aurora

doi:10.7774/cevr.2021.10.3.298

Cited by 12 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, dermatologists should be aware of this and all other possible cutaneous reactions associated with the COVID-19 vaccine, to promptly recognize and, if needed, treat them, minimizing the discomfort of the patients and thereby encouraging the population to undergo vaccination. 11,12 Lastly, we highlight the importance of reporting adverse reactions,…”

Section: Discussionmentioning

confidence: 94%

Lichen planus flare following COVID‐19 vaccination: A case report

Herzum

Burlando

Molle

et al. 2021

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

We report the third case of cutaneous lichen planus (LP) following COVID‐19 BNT162b2 vaccination in a 59‐year‐old woman with previous LP. The reactivation of LP in patients with dormant LP suggests a possible vaccine‐induced immune dysregulation. We suggest that the already described vaccine‐induced upregulation of Th1 response may play a relevant role in LP reactivation, through an increase in inflammatory cytokines involved in the pathogenesis of LP. Interestingly, LP has already been associated with vaccinations and viral infections including COVID‐19 disease. However, the exact mechanism underlying LP (re)activation after Pfizer‐BiotNtech COVID‐19 vaccination is still widely unknown and needs to be further investigated.

show abstract

Section: Discussionmentioning

confidence: 94%

Lichen planus flare following COVID‐19 vaccination: A case report

Herzum

Burlando

Molle

et al. 2021

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ten out of 21 developed macular or urticarial rashes, which resolved with antihistamine or spontaneously, similarly to cases reported in the literature. 2 , 3 , 4 , 5 , 6 Two patients presented generalized pruritic rash shortly after vaccination (≤4 h), possibly representing immediate hypersentivity type I reactions against vaccine excipients. 2 , 3 , 4 , 5 , 6 …”

Section: Discussionmentioning

confidence: 99%

“… 2 , 3 , 4 , 5 , 6 Two patients presented generalized pruritic rash shortly after vaccination (≤4 h), possibly representing immediate hypersentivity type I reactions against vaccine excipients. 2 , 3 , 4 , 5 , 6 …”

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions to COVID‐19 vaccine at the dermatology primary care

Burlando

Herzum

Micalizzi

et al. 2021

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) vaccines can cause adverse reactions, mainly from vaccine-induced immune responses. Some of these may also involve the skin and worry unaware patients. A better understanding of such adverse reactions may reduce concerns and help promote the vaccination of large population groups. Methods: All the reports of patients admitted to our Dermatology Primary Care, from March 2021 to June 2021, were retrospectively examined to collect descriptive data on skin reactions arising after COVID-19 vaccination. Results: Out of 200 vaccinated patients admitted to the Dermatology Primary Care, 21 (10.5%) referred cutaneous reactions with onset after vaccination. Only one patient required hospitalization for generalized bullous erythema multiforme, which occurred 48 h after the second vaccine dose. The other patients' cutaneous reactions to vaccination were of mild/moderate degree.Three patients presented exacerbation of their cutaneous diseases. Conclusions: Cutaneous reactions observed in our sample were mostly mild or moderate. Awareness must be raised to recognize and treat eventual severe reactions. Future studies are needed to assess the incidence of cutaneous reactions following COVID-19 vaccination.

show abstract

“…In cases where the same sample was used for more than one study, all studies were reviewed to determine the extent to which there may be duplication in the reported outcomes between studies. The full text of selected studies was reviewed, and data on demographics, article type, number of reported cases with cutaneous involvement, vaccine, and rash type (morphology) were extracted from articles texts, tables, figures, and summarized through a descriptive table (Table 1)…”

Section: Methodsmentioning

confidence: 99%

SARS‐CoV‐2 vaccine‐related cutaneous manifestations: a systematic review

et al. 2022

View full text Add to dashboard Cite

To date, over 250 million people have been reportedly infected by COVID‐19 disease, which has spread across the globe and led to approximately 5.1 million fatalities. To prevent both COVID‐19 and viral transmission, DNA‐based/RNA‐based vaccines, non‐replicating viral vector vaccines, and inactivated vaccines have been recently developed. However, a precise clinical and histological characterization of SARS‐CoV‐2 vaccine‐related dermatological manifestations is still lacking. A systematic review of 229 articles was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, in order to provide an extensive overview of SARS‐CoV‐2 vaccine‐related skin manifestations. Data on demographics, number of reported cases with cutaneous involvement, vaccine, and rash type (morphology) were extracted from articles and summarized. A total of 5941 SARS‐CoV‐2 vaccine‐related dermatological manifestations were gathered. Local injection‐site reactions were the most frequently observed, followed by rash/unspecified cutaneous eruption, urticarial rashes, angioedema, herpes zoster, morbilliform/maculopapular/erythematous macular eruption, pityriasis rosea and pityriasis rosea‐like eruptions, and other less common dermatological manifestations. Flares of pre‐existing dermatological conditions were also reported. Cutaneous adverse reactions following SARS‐CoV‐2 vaccine administration seem to be heterogeneous, rather infrequent, and not life‐threatening. Vaccinated patients should be monitored for skin manifestations, and dermatological evaluation should be offered, when needed.

show abstract

Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80

Cited by 12 publications

References 6 publications

Lichen planus flare following COVID‐19 vaccination: A case report

Lichen planus flare following COVID‐19 vaccination: A case report

Cutaneous reactions to COVID‐19 vaccine at the dermatology primary care

SARS‐CoV‐2 vaccine‐related cutaneous manifestations: a systematic review

Contact Info

Product

Resources

About